Page last updated: 2024-10-16

adenine and Leucocythaemia

adenine has been researched along with Leucocythaemia in 41 studies

Research Excerpts

ExcerptRelevanceReference
"After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose."9.07Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991)
"After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose."5.07Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991)
"Certain D-arabinosyl nucleosides, notably arabinosyl cytosine (araC) and arabinosyl adenine (araA), are useful in the treatment of certain leukemias and some DNA virus infections, respectively."4.75The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA). ( Cohen, SS, 1977)
" A simple analytical method using high-performance LC/electrospray ionization-tandem mass spectrometry has been developed and validated for simultaneous quantification of BCR-ABL and Bruton's TKIs used for chronic leukemia (imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib) in human plasma."4.02High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. ( Fukuhara, N; Hirasawa, T; Kikuchi, M; Maekawa, M; Mano, N; Ogura, J; Onishi, Y; Onodera, K; Sato, T; Sato, Y; Shigeta, K; Takasaki, S, 2021)
" Here side effects of ibrutinib have been summarized and important considerations in the management of these adverse events have been reviewed."2.61Management of adverse effects/toxicity of ibrutinib. ( Paydas, S, 2019)

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-199025 (60.98)18.7374
1990's2 (4.88)18.2507
2000's2 (4.88)29.6817
2010's8 (19.51)24.3611
2020's4 (9.76)2.80

Authors

AuthorsStudies
Bon, C1
Barbachowska, M1
Djokovic, N1
Ruzic, D1
Si, Y1
Soresinetti, L1
Jallet, C1
Tafit, A1
Halby, L1
Nikolic, K1
Arimondo, PB1
Hu, EY1
Blachly, JS1
Saygin, C1
Ozer, HG1
Workman, SE1
Lozanski, A1
Doong, TJ1
Chiang, CL1
Bhat, S1
Rogers, KA1
Woyach, JA2
Coombes, KR1
Jones, D1
Muthusamy, N2
Lozanski, G1
Byrd, JC2
Hirasawa, T1
Kikuchi, M1
Shigeta, K1
Takasaki, S1
Sato, Y1
Sato, T1
Ogura, J1
Onodera, K1
Fukuhara, N1
Onishi, Y1
Maekawa, M1
Mano, N1
Feldman, RC1
Hyman, DA1
Price, WN1
Ratain, MJ1
Paydas, S1
Yun, SM1
Jung, JH1
Jeong, SJ1
Sohn, EJ1
Kim, B1
Kim, SH1
Dubovsky, JA1
Beckwith, KA1
Natarajan, G1
Jaglowski, S1
Zhong, Y1
Hessler, JD1
Liu, TM1
Chang, BY1
Larkin, KM1
Stefanovski, MR1
Chappell, DL1
Frissora, FW1
Smith, LL1
Smucker, KA1
Flynn, JM1
Jones, JA1
Andritsos, LA1
Maddocks, K1
Lehman, AM1
Furman, R1
Sharman, J1
Mishra, A1
Caligiuri, MA1
Satoskar, AR1
Buggy, JJ1
Johnson, AJ1
Pabst, C1
Krosl, J1
Fares, I1
Boucher, G1
Ruel, R1
Marinier, A1
Lemieux, S1
Hébert, J1
Sauvageau, G1
Palmeira dos Santos, C1
Pereira, GJ1
Barbosa, CM1
Jurkiewicz, A1
Smaili, SS1
Bincoletto, C1
Kim, S1
Hong, JH1
Leong, DP1
Caron, F1
Hillis, C1
Duan, A1
Healey, JS1
Fraser, G1
Siegal, D1
Yang, L1
Yu, Y1
Kang, R1
Yang, M1
Xie, M1
Wang, Z1
Tang, D1
Zhao, M1
Liu, L1
Zhang, H1
Cao, L1
AUDRY, M1
SCOTT, JL1
VANDEVOORDE, JP1
HANSEN, HJ1
NADLER, SB1
FURUKAWA, T1
RIMAN, J1
SAWITSKY, A1
RUOHANI, J1
LEVY, RN1
EHRHART, H1
SCHEFFEL, G1
SATO, K1
LEPAGE, GA1
Sharif, FA1
Yilmaz, Y1
Zieske, A1
Qumsiyeh, MB1
Burchenal, JH1
Dollinger, M1
Butterbaugh, J1
Stoll, D1
Giner-Sorolla, A1
Morita, Y1
Siraganian, RP1
Kefford, RF1
Fox, RM1
Barnes, MJ1
Taylor, GA1
Newell, DR1
Cohen, SS1
Fuska, J2
Fuskova, A2
Proksa, B1
Kaneko, K1
Fujimori, S1
Kumakawa, T1
Kamatani, N1
Akaoka, I1
O'Brien, S1
Benvenuto, JA1
Estey, E1
Beran, M1
Felder, TB1
Keating, M1
Tsutani, H1
Yoshimura, T1
Uchida, M1
Kamiya, K1
Ueda, T1
Nakamura, T1
Weber, G1
Jayaram, HN1
Lapis, E1
Natsumeda, Y1
Yamada, Y1
Yamaji, Y1
Tricot, GJ1
Hoffman, R1
Huang, P1
Plunkett, W1
Wolberg, G1
Zimmerman, TP1
Ohlsson-Wilhelm, BM1
Farley, BA1
Rudolph, NS1
Rowley, PT1
Smith, CM1
Fontenelle, LJ1
Lalanne, M1
Henderson, JF1
Rosman, M2
Williams, HE1
Lee, MH1
Creasey, WA1
Sartorelli, AC1
Wilmanns, W1
Smith, JL1
Omura, GA1
Krakoff, IH1
Balis, ME1
Kano, A1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia[NCT01217749]Phase 1/Phase 271 participants (Actual)Interventional2010-12-31Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]Phase 1/Phase 2133 participants (Actual)Interventional2010-05-31Completed
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]40 participants (Actual)Observational [Patient Registry]2018-12-01Completed
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia[NCT02056782]Phase 112 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE (NCT01217749)
Timeframe: From first dose of study treatment to within 30 days of last dose or until study closure

Interventionparticipants (Number)
Group 127
Group 220
Group 324

Percentage of Participants Achieving Response

The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results. (NCT01217749)
Timeframe: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months

Interventionpercentage of participants (Number)
Group 192.6
Group 280.0
Group 370.8

Progression Free Survival (PFS) at 12 Months

"Progressive disease for CLL (Hallek) is characterized by ≥1 of the following:~Appearance of any new lesion, eg lymph nodes (> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates~Increase of ≥50%~in longest diameter of any previous site~in hepatomegaly or splenomegaly~in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen~Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir:~Appearance of a new lesion(s) >1.5 cm in any axis, ≥ 50% increase in the SPD of >1 node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis~Lesions PET+ if FDG-avid lymphoma or PET+ before therapy~50% increase from nadir in the SPD of any liver or spleen lesions~New or recurrent BM involvement~Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen" (NCT01217749)
Timeframe: From first dose of study treatment until disease progression, death, or until 12 months

Interventionpercentage of event free participants (Mean)
Group 188.7
Group 285.0
Group 375.0

Safety During Dose-Limiting Toxicity (DLT) Observation Period

Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2 (NCT01217749)
Timeframe: 56 days for Group 1 and 28 days for Group 2

Interventionparticipants who experienced DLT (Number)
Group 10
Group 20

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention (Number)
Food Effect Cohort1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

InterventionParticipants (Number)
PCI-32765116
Food Effect11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive71
Relapsed/ Refractory75.3
Food Effect56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive96.3
Relapsed/ Refractory73.6
Food- EffectNA

Number of Subjects Who Achieved a Morphologic Complete Remission

"A secondary endpoint of this study was to determine whether there was preliminary evidence of an effect of dociparstat on remission rate following cytarabine and idarubicin induction in acute myeloid leukemia (AML) patients, which included complete remission (CR) rate (with neutrophil and platelet count recovery) after the first induction cycle.~Morphologic CR was defined as absolute neutrophil count (ANC) >1000/μL, platelet count >100,000/μL, <5% bone marrow blasts, no Auer rods, and no evidence of extramedullary disease." (NCT02056782)
Timeframe: Day 1 to Day 35 (35 days)

InterventionParticipants (Count of Participants)
Dociparstat11

Time (Days) to Transfusion-independent Platelet Recovery (Platelet Counts Values ≥ 20,000/μL and ≥ 50,000/μL Without a Platelet Transfusion)

A primary endpoint of this study was evidence of an effect of dociparstat on transfusion independent platelet recovery time. The time (days) to transfusion-independent platelet recovery will be defined as the number of days from the first day of chemotherapy until the first of 5 consecutive days with platelet counts values ≥ 20,000/μL and ≥ 50,000/μL without a platelet transfusion. (NCT02056782)
Timeframe: Day 1 to Day 35 (35 days)

Interventiondays (Mean)
Platelet count of ≥20,000/µLPlatelet count of ≥50,000/µL
Dociparstat21.323.1

Reviews

3 reviews available for adenine and Leucocythaemia

ArticleYear
Management of adverse effects/toxicity of ibrutinib.
    Critical reviews in oncology/hematology, 2019, Volume: 136

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug-Related Side Effects and Adv

2019
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
    Blood, 2016, 07-07, Volume: 128, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Incidence; Leuke

2016
The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA).
    Cancer, 1977, Volume: 40, Issue:1 Suppl

    Topics: Adenine; Adenosine Deaminase Inhibitors; Adenosine Monophosphate; Adenosine Triphosphate; Animals; A

1977

Trials

2 trials available for adenine and Leucocythaemia

ArticleYear
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Blood, 2013, Oct-10, Volume: 122, Issue:15

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur

2013
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    Cancer research, 1991, Feb-01, Volume: 51, Issue:3

    Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evalu

1991

Other Studies

36 other studies available for adenine and Leucocythaemia

ArticleYear
Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies.
    Future medicinal chemistry, 2022, Volume: 14, Issue:8

    Topics: Adenine; Antidotes; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Molecular Docking Simulati

2022
LC-FACSeq is a method for detecting rare clones in leukemia.
    JCI insight, 2020, 06-18, Volume: 5, Issue:12

    Topics: Adenine; Clonal Evolution; Clone Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Mu

2020
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
    Biomedical chromatography : BMC, 2021, Volume: 35, Issue:8

    Topics: Adenine; Aniline Compounds; Chromatography, Liquid; Dasatinib; Drug Monitoring; Female; High-Through

2021
Negative innovation: when patents are bad for patients.
    Nature biotechnology, 2021, Volume: 39, Issue:8

    Topics: Adenine; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Patents as Topic; Patient Harm; Piperidi

2021
Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells.
    Phytotherapy research : PTR, 2014, Volume: 28, Issue:3

    Topics: Abietanes; Adenine; AMP-Activated Protein Kinases; Autophagy; Cell Line, Tumor; Extracellular Signal

2014
Identification of small molecules that support human leukemia stem cell activity ex vivo.
    Nature methods, 2014, Volume: 11, Issue:4

    Topics: Adenine; Cell Culture Techniques; Culture Media, Serum-Free; Drug Screening Assays, Antitumor; Human

2014
Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine‑induced death of leukaemia cells.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:6

    Topics: Adenine; Antimalarials; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

2014
Synthesis and Biological Evaluation of 9-Deazaadenine 5'-Deoxy-6',6'-Difluoro-Carbocyclic C-Nucleoside Phosphonic Acid Derivatives.
    Nucleosides, nucleotides & nucleic acids, 2015, Volume: 34, Issue:10

    Topics: Adenine; Animals; Anti-HIV Agents; Antineoplastic Agents; Cell Line, Tumor; Drug Design; HIV-1; Huma

2015
Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Adenine; Autophagy; Blotting, Western; Cell Proliferation; Cells, Cultured; Child; Drug Resistance,

2012
[Action of adenine on leukopoiesis].
    La Semaine des hopitaux: therapeutique, 1960, Volume: 36

    Topics: Adenine; Humans; Leukemia; Leukopoiesis

1960
Human leukocyte metabolism in vitro. I. Incorporation of adenine-8-C-14 and formate-C-14 into the nucleic acids of leukemic leukocytes.
    The Journal of clinical investigation, 1962, Volume: 41

    Topics: Adenine; Formates; Humans; In Vitro Techniques; Leukemia; Leukocytes; Nucleic Acids

1962
METABOLISM OF LEUKEMIC CELLS IN CULTURE; AZASERINE INHIBITION OF J-128 (OSGOOD).
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1964, Volume: 115

    Topics: Adenine; Azaserine; Carbon Isotopes; Glycine; Guanine; Hypoxanthines; Imidazoles; Leukemia; Metaboli

1964
[STUDIES ON TISSUE CULTURE OF LEUKEMIC CELLS IN CHILDREN. 1. CONSIDERATIONS ON THE BASIC CONDITIONS FOR THE 1ST CULTURE].
    Nihon Shonika Gakkai zasshi. Acta paediatrica Japonica, 1964, Volume: 68

    Topics: Adenine; Adolescent; Child; Corrinoids; Hematinics; Humans; Immune Sera; Infant; Leucovorin; Leukemi

1964
EXPERIMENTAL VIRAL LEUKAEMIA AS A RHYTHMIC GROWTH PROCESS. II. SYSTEMATIC FLUCTUATION OF THE ADENOSINETRIPHOSPHATE (ATP) CONTENT AND CHANGES IN THE FREE ADENINE NUCLEOTIDE (ATP, ADP, AMP) POOL IN LEUKAEMIC CELLS DURING THE LEUKAEMIC PROCESS.
    Folia biologica, 1964, Volume: 10

    Topics: Adenine; Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate

1964
DRUG FEVER PRODUCED BY SIX-MERCAPTOPURINE.
    Annals of internal medicine, 1964, Volume: 61

    Topics: Adenine; Antineoplastic Agents; Drug Therapy; Fever; Hematocrit; Leukemia; Leukocyte Count; Mercapto

1964
[STUDIES ON LEUKOCYTE METABOLISM. NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD) CONTENT OF NORMAL AND LEUKEMIC LEUKOCYTES IN MAN. II].
    Klinische Wochenschrift, 1965, Mar-15, Volume: 43

    Topics: Adenine; Blood Cell Count; Blood Chemical Analysis; Erythrocytes; Humans; Leukemia; Leukemia, Lympho

1965
METABOLIC EFFECTS OF AN ANTIBIOTIC, NSC-51954, ON SUSCEPTIBLE AND RESISTANT TUMOR CELLS.
    Cancer research, 1965, Volume: 25

    Topics: Adenine; Animals; Anti-Bacterial Agents; Carbon Isotopes; Carcinoma, Ehrlich Tumor; DNA; DNA, Neopla

1965
Natural killer cell lymphoma/leukemia with homozygous loss of p27/kip1.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:6

    Topics: Adenine; Aged; Amino Acid Sequence; Base Sequence; Cyclin-Dependent Kinase Inhibitor p27; Cytogeneti

2005
Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
    Biochemical pharmacology, 1967, Volume: 16, Issue:3

    Topics: Adenine; Animals; Body Weight; Cytarabine; Drug Antagonism; Drug Synergism; Fluorouracil; Guanine; L

1967
Inhibition of IgE-mediated histamine release from rat basophilic leukemia cells and rat mast cells by inhibitors of transmethylation.
    Journal of immunology (Baltimore, Md. : 1950), 1981, Volume: 127, Issue:4

    Topics: Adenine; Adenosine; Animals; Basophils; Female; Histamine Release; Homocysteine; Immunoglobulin E; L

1981
Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:2

    Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Cell Survival; Cells, Cultured; Coform

1983
Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells.
    Biochemical pharmacology, 2000, Feb-15, Volume: 59, Issue:4

    Topics: Adenine; Antimetabolites, Antineoplastic; Child; Guanine; Humans; Inosine; Leukemia; Methotrexate; P

2000
The in vitro-in vivo effect of antibiotic PSX-1 on lympholeukaemia L-5178.
    The Journal of antibiotics, 1976, Volume: 29, Issue:9

    Topics: Adenine; Animals; Antibiotics, Antineoplastic; Cells, Cultured; Leukemia; Male; Mice; Neoplasm Trans

1976
New potential cytotoxic and antitumor substances I. In vitro effect of bikaverin and its derivatives on cells of certain tumors.
    Neoplasma, 1975, Volume: 22, Issue:3

    Topics: Adenine; Animals; Carcinoma, Ehrlich Tumor; Cells, Cultured; DNA, Neoplasm; In Vitro Techniques; Leu

1975
Disturbance in the metabolism of 5'-methylthioadenosine and adenine in patients with neoplastic diseases, and in those with a deficiency in adenine phosphoribosyltransferase.
    Metabolism: clinical and experimental, 1991, Volume: 40, Issue:9

    Topics: Adenine; Adenine Phosphoribosyltransferase; Adenosine; Adult; Aged; Deoxyadenosines; Female; Humans;

1991
Purine nucleotide synthesis during terminal differentiation.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Adenine; Cell Differentiation; Cell Division; Dimethyl Sulfoxide; Glycine; Humans; Hypoxanthines; Le

1989
Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Advances in enzyme regulation, 1988, Volume: 27

    Topics: Adenine; Aged; Allopurinol; Animals; Drug Evaluation; Female; Guanine; Guanosine Triphosphate; Human

1988
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
    Biochemical pharmacology, 1987, Sep-15, Volume: 36, Issue:18

    Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia co

1987
Effects of adenosine deaminase inhibitors on lymphocyte-mediated cytolysis.
    Annals of the New York Academy of Sciences, 1985, Volume: 451

    Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Animals; Cell Line; Coformycin; Cytotoxicity, Im

1985
Erythroid induction of K562 human leukemia cells: enhancement by purines.
    Archives of biochemistry and biophysics, 1985, Volume: 239, Issue:2

    Topics: Adenine; Cell Cycle; Cell Division; Cell Line; Drug Synergism; Guanine; Hemoglobins; Humans; Hypoxan

1985
Inhibition of purine ribonucleotide and phosphoribosyl pyrophosphate synthesis by 6-cyclopentylthio-9-hydroxymethylpurine and structurally related compounds.
    Cancer research, 1974, Volume: 34, Issue:3

    Topics: Adenine; Animals; Carbon Radioisotopes; Carcinoma, Ehrlich Tumor; Cell Line; Cells, Cultured; Cyclop

1974
Leukocyte purine phosphoribosyltransferases in human leukemias sensitive and resistant to 6-thiopurines.
    Cancer research, 1973, Volume: 33, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antimetabolites; Drug Resistance; Female; Guanine; Humans; Hypoxan

1973
Mechanisms of resistance to 6-thiopurines in human leukemia.
    Cancer research, 1974, Volume: 34, Issue:8

    Topics: Adenine; Alkaline Phosphatase; Drug Resistance; Guanine; Humans; Hypoxanthines; Leukemia; Leukemia,

1974
Synthesis of purine nucleotides in human and leukemic cells. Interaction of 6-mercaptopurine and allopurinol.
    Advances in experimental medicine and biology, 1973, Volume: 41

    Topics: Adenine; Allopurinol; Bone Marrow; Bone Marrow Cells; Carbon Radioisotopes; Cell-Free System; Chroma

1973
IMP: and AMP:pyrophosphate phosphoribosyltransferase in leukemic and normal human leukocytes.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1971, Volume: 136, Issue:4

    Topics: Adenine; Carbon Isotopes; Erythrocytes; Guanine; Humans; Hypoxanthines; In Vitro Techniques; Leukemi

1971
[Nucleic acid metabolism of leukemic leukocytes. 2. The effect of 6-mercaptopurine on nucleic acid metabolism of leukemic leukocytes].
    Naika hokan. Japanese archives of internal medicine, 1968, Volume: 15, Issue:8

    Topics: Adenine; Carbon Isotopes; Guanine; Humans; Hypoxanthines; Leukemia; Leukocytes; Mercaptopurine; Nucl

1968